Clinical Trial News and Research

RSS

Initial results of the CURRENT-OASIS 7 clinical trial due for release

Today, the OASIS study group will present initial results of the CURRENT-OASIS 7 clinical trial at the European Society of Cardiology congress in Barcelona. Sanofi-aventis and Bristol-Myers Squibb, co-commercialization and co-development partners for PLAVIX(clopidogrel bisulfate), were sponsors of the study.

30 Aug 2009

Phase 2B clinical trial results of oral vernakalant to be presented at the ESC Congress 2009

Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that Dr. Christian Torp-Pedersen is scheduled to present detailed findings from the Phase 2b clinical trial of vernakalant (oral) at the European Society of Cardiology (ESC) Congress 2009, being held in Barcelona, Spain from August 29 to September 2, 2009.

29 Aug 2009

Genzyme’s supplemental NDA for treating adult AML with Clolar to be discussed by the FDA

Genzyme Corporation (Nasdaq: GENZ) announced today that its supplemental New Drug Application for Clolar® (clofarabine) will be discussed Tuesday, September 1 at a public meeting of the FDA’s Oncologic Drugs Advisory Committee in Silver Spring, Maryland. The panel is expected to consider the clinical trial results Genzyme submitted to support the approval and labeling of Clolar to treat older adult patients with acute myeloid leukemia (AML), the most common type of acute leukemia in adults.

29 Aug 2009

Facet Biotech And Trubion to jointly develop and commercialize the TRU-016 SMIP protein therapeutic

Facet Biotech Corporation (Nasdaq: FACT) and Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced an agreement for the joint worldwide development and commercialization of TRU-016, a product candidate in phase 1 clinical development for chronic lymphocytic leukemia (CLL).

28 Aug 2009

CNS Response raises funds through private placement for general corporate purposes

CNS Response, Inc. (OTCBB: CNSO) (the "Company") today announced that it has completed a closing of its private placement, resulting in gross proceeds to the Company of approximately $2,000,000.

28 Aug 2009

Boston Scientific to discuss final results of MADIT-CRT trial at the European Society of Cardiology Congress

Boston Scientific Corporation today announced the schedule of the Company's major events and news announcements for the European Society of Cardiology (ESC) Congress, which runs from August 29 to September 2 in Barcelona. Highlights include final results from the MADIT-CRT trial and two-year results from the SYNTAX trial.

28 Aug 2009

Thrombogenics issues business update and half year results

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update and its half year results for the six month period ending 30 June, 2009.

28 Aug 2009

Gen-Probe commences its PROGENSA PCA3 assay clinical trial

Gen-Probe Incorporated announced today that the Company has begun a clinical trial intended to secure U.S. regulatory approval of its PROGENSA(R) PCA3 assay, a new molecular test that may help determine the need for a repeat prostate biopsy.

28 Aug 2009

Infectious Disease Research Institute commences clinical trial of its leishmaniasis vaccine in Sudan

IDRI (Infectious Disease Research Institute) announced today the start of a clinical trial in Sudan to test its leishmaniasis vaccine candidate for the treatment of post kala-azar dermal leishmaniasis (PKDL), a complication of visceral leishmaniasis (VL) which is observed in 50% of patients treated for VL in the country, predominantly affecting children.

28 Aug 2009

Medical journal article highlights the challenges faced by healthcare providers for treating patients with non-healing wounds

Cardium Therapeutics today reported that a recent medical journal article highlights the challenges facing healthcare providers with respect to finding optimal treatments for patients with non-healing wounds.

28 Aug 2009

Ochsner Medical Center selected to participate as an FDA investigative site in the PARTNER clinical trial

On Tuesday, August 11, 2009, an 82-year old New Orleans resident with severe aortic stenosis successfully had a heart valve replaced at Ochsner Medical Center using the same technique as angioplasty, a far cry from the traditional open heart procedure. Patients who are considered high-risk or non-operable for conventional open heart valve surgery now have a potential new research option available regionally only through The John Ochsner Heart & Vascular Institute.

28 Aug 2009

Gen-Probe commences clinical study to secure U.S. approval of the PROGENSA PCA3 assay

DiagnoCure Inc. (TSX: CUR) announced that Gen-Probe, Inc. (NASDAQ: GPRO), its partner for the development and commercialization of the PCA3 prostate cancer test, has confirmed today the beginning of a U.S. clinical study intended to secure U.S. regulatory approval of the PROGENSA(R) PCA3 assay, a new molecular test that may help determine the need for a repeat prostate biopsy.

28 Aug 2009

Geron provides additional comments on the recent clinical hold of Spinal Cord Injury IND

Geron Corporation today provided additional comments on the recent clinical hold on its Spinal Cord Injury IND.

27 Aug 2009

Medgenics' EPODURE tissue Biopumps platform technology effective in maintaining hemoglobin levels

Medgenics is pleased to announce that one of the patients, who was treated with the Company’s EPODURE tissue Biopumps almost 11 months ago, continues to be effectively treated for anemia without a single erythropoietin (EPO) injection. This patient (#2) was dependent on frequent injections of the therapeutic protein (EPO) for the 18 months prior to receiving a single administration of 3 tiny EPODURE tissue Biopumps in the Company’s phase I/II anemia trial in Israel.

27 Aug 2009

New Associate Director of Business Development appointed by ERT

ERT, announced the appointment of a new Associate Director of Business Development - Japan, Miki Stevens. In this new role, Ms. Stevens will work with ERT's Japanese partner, Site Support Institute (SSI), to facilitate sales activities and to provide enhanced in-country support of Japanese sponsors and clinical trial sites.

27 Aug 2009

Clinical data added to ORENCIA labeling help treat patients with rheumatoid arthritis

Bristol-Myers Squibb Company announced today that clinical data added to the labeling for ORENCIA (abatacept) support use of ORENCIA for patients with moderate to severe rheumatoid arthritis of less than or equal to two years duration.

27 Aug 2009

CardioMEMS raises $22.1M to fund clinical trial of its heart failure pressure measurement system

CardioMEMS, Inc., a medical technology company that has developed and is commercializing proprietary wireless sensing and communication technology for the human body, today announced the completion of a $22.1M financing. The financing provides the company with additional capital to fund the company's CHAMPION clinical trial.

27 Aug 2009

Angiotensin arrests lung tumor growth by inhibiting blood vessel formation

In new animal research done by investigators at Wake Forest University School of Medicine, scientists have discovered a treatment effective in mice at blocking the growth and shrinking the size of lung cancer tumors, one of the leading causes of cancer death in the world.

27 Aug 2009

BioAlliance Pharma posts revenue of €4.1 million for the first half of 2009

BioAlliance Pharma SA (Paris:BIO) (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today presented its consolidated half-year accounts to June 30, 2009.

27 Aug 2009

Angeion Corporation announces financial results for third-quarter fiscal 2009

For the 2009 third quarter, Angeion posted a net loss of $173,000, or $0.04 per diluted share, on revenues of $6.2 million. This represents a sequential improvement from a 2009 second-quarter net loss of $225,000, or $0.05 per diluted share, also on revenues of $6.2 million.

27 Aug 2009

Clinical Trial News and Research

Initial results of the CURRENT-OASIS 7 clinical trial due for release

Phase 2B clinical trial results of oral vernakalant to be presented at the ESC Congress 2009

Genzyme’s supplemental NDA for treating adult AML with Clolar to be discussed by the FDA

Facet Biotech And Trubion to jointly develop and commercialize the TRU-016 SMIP protein therapeutic

CNS Response raises funds through private placement for general corporate purposes

Boston Scientific to discuss final results of MADIT-CRT trial at the European Society of Cardiology Congress

Thrombogenics issues business update and half year results

Gen-Probe commences its PROGENSA PCA3 assay clinical trial

Infectious Disease Research Institute commences clinical trial of its leishmaniasis vaccine in Sudan

Medical journal article highlights the challenges faced by healthcare providers for treating patients with non-healing wounds

Ochsner Medical Center selected to participate as an FDA investigative site in the PARTNER clinical trial

Gen-Probe commences clinical study to secure U.S. approval of the PROGENSA PCA3 assay

Geron provides additional comments on the recent clinical hold of Spinal Cord Injury IND

Medgenics' EPODURE tissue Biopumps platform technology effective in maintaining hemoglobin levels

New Associate Director of Business Development appointed by ERT

Clinical data added to ORENCIA labeling help treat patients with rheumatoid arthritis

CardioMEMS raises $22.1M to fund clinical trial of its heart failure pressure measurement system

Angiotensin arrests lung tumor growth by inhibiting blood vessel formation

BioAlliance Pharma posts revenue of €4.1 million for the first half of 2009

Angeion Corporation announces financial results for third-quarter fiscal 2009

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer